Men who take a certain class of cholesterol-lowering medicine, otherwise known as statins, may be 60 percent less likely to be diagnosed with high-grade prostate cancer. Some of the results of this powerful study involving more than 55,000 men were discussed at the Prostate Cancer Research Program’s (PCRP’s) Innovative Minds in Prostate Cancer Today . . . → Read More: Study: Statin use may reduce risk of high-grade prostate cancer
|
|||||
|
A new study suggests that combining two experimental anticancer peptide agents might simultaneously block formation of new tumor blood vessels while also inhibiting the growth of tumor cells. This early test of the two agents in a breast cancer model suggests that the double hit can stifle tumor progression, avoid drug resistance and . . . → Read More: New study: Two peptide agent combination might block tumor growth Alum is an adjuvant (immune booster) used in many common vaccines, and Canadian researchers have now discovered how it works. The research by scientists from the University of Calgary’s Faculty of Medicine is published in the March 13 online edition of Nature Medicine. The new findings will help the medical community produce more effective . . . → Read More: New findings may open doors for vaccine development against HIV, tuberculosis Scientists are collaborating on a new international research project to identify antibiotics that can kill tuberculosis and fight resistant strains. “We want to accelerate the discovery of new compounds that can be turned into effective drugs,” said Professor Tony Maxwell from the John Innes Centre, a key player in “More Medicines for Tuberculosis”, a . . . → Read More: New international research project to identify antibiotics against tuberculosis Bayer HealthCare Pharmaceuticals Inc. announced today that the U.S. Food and Drug Administration has approved Gadavist™ (gadobutrol) Injection, a macrocyclic gadolinium-based contrast agent (GBCA), for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) . . . → Read More: Bayer receives FDA approval for Gadavist Injection Taiho Pharmaceutical Co., Ltd., and its parent company, Otsuka Holdings Co., Ltd., announced today that the European Commission (EC) has granted marketing authorization for Teysuno™ (S-1), a novel oral anti-cancer agent indicated for the treatment of adults with advanced gastric cancer when given in combination with cisplatin. The authorization is applicable to the 27 . . . → Read More: EC grants marketing authorization for Taiho’s Teysuno to treat gastric cancer Scientists are collaborating on a new international research project to identify antibiotics that can kill tuberculosis and fight resistant strains. “We want to accelerate the discovery of new compounds that can be turned into effective drugs,” said Professor Tony Maxwell from the John Innes Centre, a key player in “More Medicines for Tuberculosis”, a . . . → Read More: New international research project to identify antibiotics against tuberculosis Scientists are collaborating on a new international research project to identify antibiotics that can kill tuberculosis and fight resistant strains. “We want to accelerate the discovery of new compounds that can be turned into effective drugs,” said Professor Tony Maxwell from the John Innes Centre, a key player in “More Medicines for Tuberculosis”, a . . . → Read More: New international research project to identify antibiotics against tuberculosis As the United Nations, the European Commission, and the United States Food and Drug Administration (FDA) evaluate the health and environmental risks associated with mercury, a known neurotoxin, carcinogen, mutagen, teratogen, and immune-system disruptor, new research continues to fuel concerns about Thimerosal (THIM), a mercury-based compound used as a preservative in inactivated flu vaccines. . . . → Read More: New research concerns about use of Thimerosal in inactivated flu vaccines Scientific advances at The Scripps Research Institute were key to laying the foundation for the new drug Benlysta® (belimumab), approved today by the U.S. Food and Drug Administration. Benlysta®, which treats the most common type of lupus, is the first in a new class of pharmaceuticals that prevents the body from attacking its own . . . → Read More: Scientific advances at Scripps Research lay foundation for new lupus drug Benlysta All infant formulas, either concentrated or ready-to-feed, already contain some fluoride and, when routinely mixed with fluoridated water, increase the risk of dental fluorosis (discolored teeth), according to Dr. Howard Koh, Assistant Secretary for Health, U.S. Department of Health and Human Services (HHS) in a video commentary published on Medscape.com, March 8, 2011. . . . → Read More: Infant formulas with fluoridated water increase risk of discolored teeth PNP Therapeutics, Inc. — an early-stage Birmingham-based biopharmaceutical company created from research conducted at Southern Research Institute and The University of Alabama at Birmingham (UAB) — today announced that several major objectives have been reached in the development of its therapeutic technology platform and proprietary products for the treatment of cancer. “A number of . . . → Read More: PNP reaches several major objectives in cancer therapeutic product development Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events as outlined in the recently updated NCCN Guidelines™ for Breast Cancer. Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Breast Cancer, presented these and other . . . → Read More: Updated NCCN Guidelines for Breast Cancer outline expanded treatment options OncoVista Innovative Therapies, Inc., (OTCBB:OVIT) reported in a letter to shareholders that it is moving forward on its business plan to develop targeted, safer and more efficacious cancer treatments with reduced or no toxicity. “OncoVista is moving full-speed ahead,” said Alexander L. Weis, Ph.D., Chairman, CEO and President of OncoVista. “We are advancing . . . → Read More: OncoVista plans to advance reduced-toxicity targeted cancer treatments Researchers at UT Southwestern Medical Center have identified a chemical compound that may eventually lead to a drug that fights cancers that are dependent on a particular anti-viral enzyme for growth. The researchers are testing the compound’s effectiveness at fighting tumors in mice. If it is successful, they will then work to develop a . . . → Read More: Scientists identify chemical compound that may lead to cancer-fighting drugs |
|||||
|
Copyright © 2012 Biomed Middle East - All Rights Reserved |
|||||
